Skip to content

Quinoa Biscuit & CVD Risk Trial

Effect of a Quinoa-enriched Biscuit as Novel Food Product to Improve CVD Risk Markers in Older Adults: a Randomised Crossover Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03291548
Enrollment
40
Registered
2017-09-25
Start date
2017-02-13
Completion date
2017-06-19
Last updated
2017-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Dyslipidemias, Lipid Profile

Keywords

Quinoa, Functional food, Cardiovascular disease, Cholesterol, Lipid profile, Randomised Control Trial

Brief summary

Cardiovascular disease (CVD) is one of the most common chronic diseases in older populations, which has been increasing in line with rising overweight and obesity levels in recent years. Dietary intake is a major modifiable risk factor for CVD, and one such recommendation is to increase the intake of essential (omega-3) polyunsaturated fats in our diets, for example by consuming more oily fish. We know, however, from large population level dietary surveys, that many individuals within the United Kingdom (UK) population are not consuming enough oily fish. Therefore, alternative dietary sources of omega-3 polyunsaturated fats are required to help meet consumer needs. Quinoa is a traditional Andean seed crop consumed in a similar fashion to staple cereal grains in Europe, and the popularity of quinoa has been growing worldwide because of its nutritional content and perceived healthiness. Quinoa contains a small amount of fat, but the ratio of omega-6 and omega-3 essential fats is more favourable in quinoa than in other plant oils. An opportunity therefore exists to incorporate quinoa flour into more frequently consumed food products (e.g. biscuits) as an alternative means of increasing consumers omega-3 intake. The purpose of this study is to investigate the effect of consuming quinoa-enriched biscuits, compared to control, on markers of CVD risk over 4-weeks in older adults.

Interventions

DIETARY_SUPPLEMENTQuinoa biscuit

2x15g biscuits per day for 28 consecutive days (4 weeks).

DIETARY_SUPPLEMENTControl biscuit

2x15g biscuits per day for 28 consecutive days (4 weeks).

Sponsors

The Regional Centre for Studies in Food and Health (CREAS), Valparaíso, Chile
CollaboratorUNKNOWN
University of Ulster
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Masking description

Double Blind: researcher and particiapant unaware of the intervention assignment

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Free-living, apparently healthy adults * Aged 50-75 years at recruitment * Low fish consumers (\<2 servings/wk) * Non-smokers * Not regularly consuming plant stanols

Exclusion criteria

* Non-free-living adults * Aged \<50 or \>75 years at recruitment * Fish consumers (2 servings/wk or more) * Current smokers * Pregnant/lactating females * Coeliac disease, wheat intolerance or any other food allergy or intolerance that would prevent consumption of the biscuits * Currently taking any fish oil-containing supplement * Diagnosed with a chronic medical condition (such as diabetes; CVD autoimmune/ inflammatory disorders; cancer) * Prescribed cholesterol or blood pressure lowering medications * Daily consumption of plant stanols

Design outcomes

Primary

MeasureTime frameDescription
Total cholesterolChange from baseline compared to control armPlasma cholesterol

Secondary

MeasureTime frameDescription
LDL-cholesterolChange from baseline compared to control armmeasured in plasma
HDL-cholesterolChange from baseline compared to control armmeasured in plasma
total/HDL-cholesterol ratioChange from baseline compared to control armmeasured in plasma
Poly-unsaturated fatty acid statusChange from baseline compared to control armmeasured in plasma
TriglyceridesChange from baseline compared to control armmeasured in plasma
Inflammatory statusChange from baseline compared to control armC-reactive protein
Blood pressureChange from baseline compared to control armDiastolic and systolic
WeightChange from baseline compared to control armKg
Antioxidant statusChange from baseline compared to control armFerric-reducing Ability Plasma

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026